A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice - ASTER

Study identifier:D3461R00043

ClinicalTrials.gov identifier:NCT05637112

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

ASTER: Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

Medical condition

Systemic Lupus Erythematosus

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

500

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 27 Feb 2023
Estimated Primary Completion Date: 15 Mar 2029
Estimated Study Completion Date: 15 Mar 2029

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria